A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T cells in HLA-A2+ Patients With Synovial Sarcoma:
http://bethesdatrials.cancer.gov/clinical-research/search_detail.aspx?ProtocolID=NCI-11-C-0113
About 80% of synovial sarcoma express NY-ESO-1 but less than 1/2 of humans are HLA-A2 positive. Still it's worth it to find out whether a patient is eligible for this study considering the results of the prior study...